Evidence map›Paper›PMID 39267408›Full record

ArticleJournal of intensive care medicine2025

Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis.

Christopher Choi, Nicole De Simone, Christopher B Webb, Peiman Lahsaei, Sean G Yates, Jay S Raval, Michelle S Harkins, Donald J Hillebrand, Antonio Belli, Nicolas A Schlapobersky and 8 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of intensive care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04358003 (Plasma Adsorption in Patients With Confirmed COVID-19 Infection), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04358003 nacompletednot on this map

Plasma Adsorption in Patients With Confirmed COVID-19 Infection

TypeinterventionalSponsorMarker Therapeutics AGRan2020 to 2022Enrolled107ConditionsRespiratory Failure, ARDSArmsMarker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Christopher ChoiDepartment of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Nicole De SimoneDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Christopher B WebbDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Peiman LahsaeiDepartment of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sean G YatesDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jay S RavalDepartment of Pathology, Section of Transfusion Medicine and Therapeutic Pathology, University of New Mexico, Albuquerque, NM, USA.
Michelle S HarkinsDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Donald J HillebrandDepartment of Gastroenterology and Hepatology, University of Kansas Medical Center, Kansas City, KS, USA.
Antonio BelliDepartment of Neurosurgery, Queen Elizabeth Hospital, Birmingham, UK.
Nicolas A SchlapoberskyDepartment of Medicine and Critical Care, Christiaan Barnard Memorial Hospital, Cape Town, South Africa.
Tina S IpeDepartment of Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Grace C Banez-SeseInova Therapeutic Apheresis Services and Blood Donor Services, Sterling, VA, USA.
Vikramjit S KhangooraInova Fairfax Hospital, Falls Church, VA, USA.
Steven D NathanInova Fairfax Hospital, Falls Church, VA, USA.
Trudy M DemkoDepartment of Pulmonary and Critical Care, Reading Hospital, West Reading, PA, USA.
David C YoungDepartment of Pulmonary and Critical Care, Reading Hospital, West Reading, PA, USA.
Sigalit CaronMarker Therapeutics AG, Zug, Switzerland.
Ravi SarodeDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-4199-5158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early in the COVID-19 pandemic, patients with severe disease admitted to the intensive care unit (ICU) had a high incidence of mortality. We aimed to investigate whether plasma adsorption with the MTx.100 Column could improve survival. Methods: We performed a prospective, single-arm, multicenter, Emergency Use Authorization (EUA) trial in patients admitted to the ICU with severe COVID-19 who were worsening despite standard therapy. The primary outcome was all-cause mortality on day 28. Outcomes were analyzed using both a pre-specified performance goal (PG), and a propensity score-matched (PSM) analysis from the highest enrolling center, in which patients treated with the standard of care (SOC) plus the MTx.100 Column (n = 70) were compared to a contemporaneous cohort treated at the same center with SOC only (n = 244). Findings: Between May 21, 2020, and November 2, 2021, 107 patients with severe COVID-19 (mean age 58.1) at 7 US centers were enrolled and had at least one plasma adsorption treatment initiated. All-cause mortality on day 28 was 37.4% (40/107), an improvement over the prespecified PG (88.1%, p < 0.0001). There were no serious adverse events attributable to the MTx.100 Column or plasmapheresis. Improvements in most metabolic and inflammatory markers were also noted. The PSM analysis showed that survival odds were three times higher for MTx.100 Column-treated patients (95% CI: 1.56-5.88) than for those treated with SOC only. Interpretation: The MTx.100 Column treatment in severe COVID-19 resulted in a lower mortality than SOC by both pre-specified PG and PSM analysis.Trial Registrationclinicaltrials.gov (NCT04358003).

Indexed as

COVID-19HemoperfusionMethotrexateAgedCritical IllnessFemaleHumansIntensive Care UnitsMaleMiddle AgedPropensity ScoreProspective StudiesSARS-CoV-2Treatment OutcomeMethotrexatecritical careinfectionsintensive care unitlung infectionrespiratory failure

Identifiers

PMID39267408
PMCPMC11915769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.